Oral Wegovy Approval! Can Novo Stage a Comeback After -38%YTD?
Novo Nordisk surged 7% after receiving approval to sell an oral tablet version of its blockbuster weight-loss drug Wegovy in the U.S. The first “oral weight-loss miracle drug” is set to launch in the U.S. in early January.
NVO is down 38% this year, while LLY has repeatedly hit new highs, up 39% year to date. Both are in the obesity drug space—does this mark a potential turnaround for NVO? After this year’s sharp decline, could 2026 bring a major breakout?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments